Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.42 - $58.26
Previous CloseN/A
Volume45.38K
Average Volume (3M)463.67K
Market Cap
$3.24B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 07, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding63,474,255
10 Day Avg. Volume506,457
30 Day Avg. Volume463,669
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$74.00Price Target Upside46.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical PotentialSLK's nanobody size should allow for better local distribution at lesion sites and stronger inhibition of inflammation, which are key value propositions.
Commercial OpportunityThe commercial opportunity for sonelokimab (SLK) in HS should be significant, with potential sales that far exceed previous revenue projections.
Market PositionThe preference for secukinumab due to its cleaner safety profile and longer clinical track record suggests its strong market position.
Bears Say
Conflict Of InterestWedbush Securities does and seeks to do business with companies covered in its research reports, indicating a potential conflict of interest.
Market AdoptionComplicated payer coverage could present a headwind for sonelokimab's market adoption.
Market ReactionMLTX shares could show negative reaction if SLK's efficacy is perceived as only comparable to that of BKZ.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $31.42 and its highest was $58.26 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $3.24B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 5 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on May 12, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.124.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.71.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,474,255 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (46.71% Upside)
$74.00 (46.71% Upside)
Blogger Sentiment
Neutral
MLTX Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 113.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.10%
12-Months-Change
Fundamentals
Return on Equity
-30.57%
Trailing 12-Months
Asset Growth
-9.37%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) is a biotechnology company focused on developing innovative therapies for inflammatory diseases. The company leverages its proprietary nanobody technology to create targeted, potent, and effective treatments aimed at improving patient outcomes. MoonLake's core products include a pipeline of therapeutic candidates designed to address conditions such as dermatological, rheumatological, and gastroenterological diseases.
MLTX Stock 12 Month Forecast
Average Price Target
$74.00
▲(46.71%Upside)
Technical Analysis
Amicus
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Immunovant
―
Ownership Overview
41.86% Insiders
17.69% Mutual Funds
0.21% Other Institutional Investors
39.56% Public Companies and
Individual Investors